SCHEMBL6484773

SCHEMBL6484773

Cc1cc(Cc2ccc(F)cc2)c(=O)n2nc(C(=O)O)sc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
FPR1 P21462 2/20 0.40
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
LMNA P02545 1/20 0.37
CNR2 P34972 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
TP53 P04637 1/20 0.35
P2RY14 Q15391 1/20 0.35
RET P07949 1/20 0.34
MAPT P10636 1/20 0.34
KDR P35968 1/20 0.34
PTGER1 P34995 1/20 0.34
FPR2 P25090 1/20 0.34
MPO P05164 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6486582 0.85 MAPT (0.46) MEN1KMT2ALMNARXFP1TP53
SCHEMBL6919813 0.83 PTGER4 (0.45) LMNARXFP1TP53MAPT
SCHEMBL6475676 0.78 MEN1 (0.39) MEN1KMT2AFPR1PDE3BPDE3A
SCHEMBL6484094 0.78 LMNA (0.42) MEN1KMT2AFPR1PDE3BPDE3A
SCHEMBL6476602 0.75 FPR1 (0.44) MEN1KMT2AFPR1PDE3BPDE3A
SCHEMBL6814152 0.74 MEN1 (0.37) MEN1KMT2AFPR1PDE3BPDE3A
SCHEMBL6488680 0.72 TSHR (0.38) MEN1KMT2AFPR1LMNARXFP1
SCHEMBL6292166 0.70 PLA2G7 (0.38) MEN1KMT2ATP53MAPT
SCHEMBL6814150 0.68 TRPA1 (0.51) MAPT
SCHEMBL6485436 0.68 CNR2 (0.40) MEN1KMT2AFPR1PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004014908-A1 HETEROBICYLCIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
US-6897223-B2 Pyridine fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-05-24 US disclosed
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed
WO-2004014908-A1 HETEROBICYLCIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 MEN1 3457/4885KMT2A 2335/4885FPR1 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.